Business Wire

CQN-MULTIBANK-GROUP

12.10.2020 15:13:08 CEST | Business Wire | Press release

Share
CORRECTING and REPLACING MultiBank Group Continues Its Global Expansion by Obtaining a Regulatory License in the Dubai International Financial Centre (DIFC)

Fourth paragraph, first sentence of release dated October 11, 2020, should read: The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion... (instead of The MultiBank Group is now one of the largest financial derivatives groups in the world with a daily turnover of over US$ 1.9 Trillion...). Additionally, the multimedia has been updated to reflect new images.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005065/en/

The updated release reads:

MULTIBANK GROUP CONTINUES ITS GLOBAL EXPANSION BY OBTAINING A REGULATORY LICENSE IN THE DUBAI INTERNATIONAL FINANCIAL CENTRE (DIFC)

MultiBank Group, one of the largest online financial derivatives providers worldwide, represented by its subsidiary, MEX Australia Pty Ltd, has secured a reputable and strategic commercial license from the Dubai Financial Services Authority (DFSA).

The addition of this coveted license extends the group’s regulatory arsenal to include heavily regulated companies regulated by ASIC in Australia, BaFin in Germany, FMA in Austria, CNMV in Spain, FSC in the British Virgin Islands and CIMA in the Cayman Islands.

With the opening of the new office in the DIFC, the MultiBank Group now operates through 21 offices in 5 continents.

The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion and Gross Profit of US$85.6 million in 2019, facilitating over 90,000 trades per day and services over 280,000 customers worldwide.

Naser Taher, Chairman of MultiBank Group, said:

“The DFSA license marks yet another momentous occasion for MultiBank Group and is a testament to the strength of our group and commitment to the MENA region. The DFSA approval underscores our dedication to continue to provide our retail and institutional clients with world class services and the highest level of security of funds ”.

Courtney Fitzsimmons, CEO of MEX Australia Pty Ltd, added:

We have thoroughly enjoyed working with the DFSA throughout this process and proudly take a position here in the DIFC. In this evolving market we are thrilled to add to our regulatory arsenal, and look forward to making our mark in Dubai

For more information about the MultiBank Group, please visit www.multibankfx.com .

For more information about MEX Australia Pty Ltd (DIFC Branch), please visit www.mexexchange.ae

About MultiBank Group:

MultiBank Group was established in California, USA in 2005. It boasts a daily trading volume of over US $7.2 billion and services an extensive client base of over 280,000 customers across 90 countries. Since its launch, MultiBank Group has evolved into one of the largest online financial derivatives providers worldwide. The group offers a combination of the most advanced and award-winning trading platforms, up to a 500:1 leverage on CFD trading with products including Shares, Commodities, Indices, Digital Assets, Metals and Foreign Exchange (Forex).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye